Endure Biotherapeutics (“Endure Bio” ™) in San Diego, California, was founded by Professor Amir Zarrinpar MD, PhD, at the Zarrinpar Laboratory, UCSD. The company is developing engineered engraftable live biotherapeutics for gastrointestinal diseases by genetically engineering man’s native bacteria to express therapeutic compounds (such as anti-inflammatory cytokines). Unlike other GI focused microbiome companies, our biotherapeutics will be targeted to remain resident, delivering potentially curative solutions that endure the host environment.The company has a two-fold focus for our development programs whereby orphan disease applications would be retained by the company, such as phenylketonuria (PKU) and galactosemia, but large broad indications such as colon cancer and Type 2 diabetes would be partnered with Big Pharma/Big Biopharma companies for development and commercialization.The company’s initial Intellectual Property is based on PCT/US2018/027998: Engineered commensal bacteria and methods of use. The company has an exclusive license to this IP from UCSD and intends expand this portfolio by filing subsequent composition-of-matter IP on each new therapeutic microbe developed.The company is led by Mark S. Wilson, Engr, MBA, Founder and founding CEO of MatriSys Bioscience, a leading skin microbiome therapeutics company. Mr. Wilson has 30 years of biopharmaceutical development experience including Hybritech, Pfizer Global R&D, and Halozyme Therapeutics where he brought in the $612million deal with Hoffman La Roche, turning the company in the $5billion valuation today.

MatriSys Bioscience is a clinical stage company focused on therapeutics at the interface of the innate immune system and the human skin microbiome.

MedinCell develops custom long acting and ultra-long acting PLA-PEG-PLA formulations for small molecule, peptide, and protein therapeutics

Responsible for the commercial licensing of NexMed's NexACT(tm) Technology which provides: Penetration enhancement of topical formulations Improved bioavailability of SubQ formulations Entended half-life of oral formulations Enhanced stability

Bio-business consulting for the medical device, therapeutic, and diagnostic markets. Active pharmaceutical ingredient sourcing. Business Development partnering; in- and out-licensing.

Strategic management advice for start-up biotechnology companies

Leading, coaching, and guiding virtual drug developers to find their global partners

Founding head of business development who contributed to the growth of the organization from a private company with a $5M valuation to a publicly traded (Nasdaq: HALO) company with a $750M valuation in four years.

Founder and CEO of this start-up biopharmaceutical development organization.

Directed all outsourcing alliances for La Jolla Pfizer site.

Shortening the critical path of drug development by managing a global sourcing network of drug product and drug substance manufacturers

Directed all facets of the Materials Management function including sourcing, international logistics, supply agreements, supplier management and the launch of Viracept® - one of biotechnology's most successful product launches.

Directed all aspects of the Materials Management function including sourcing and product launches for this proprietary and multi-source parenteral manufacturing operation in Irvine, California.Contract Manufacturing Business DevelopmentBusiness Operations Analyst

Provided strategic analysis and project management for VP of Operations. Senior Operations Staff Member.